Detalhe da pesquisa
1.
CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.
Proc Natl Acad Sci U S A
; 112(15): 4725-30, 2015 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25825750
2.
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Proc Natl Acad Sci U S A
; 110(9): 3501-6, 2013 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-23382202
3.
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
Proc Natl Acad Sci U S A
; 109(17): 6656-61, 2012 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451919
4.
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Sci Transl Med
; 9(381)2017 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28298418
5.
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
J Clin Invest
; 126(7): 2610-20, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27294525
6.
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.
Oncoimmunology
; 2(6): e24452, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23894705